 we report on our third quarter 2019 financial results and discuss our plans for commercialization of cytisinicline. 
 we also provide an update on our ongoing regulatory discussions with the FDA. 
 finally, we provide an update on our ongoing discussions with potential commercialization partners for commercialization of cytisinicline and discuss the potential impact of e-cigarettes on smoking cessation and nicotine addiction.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 